Enliven Therapeutics (ELVN) Competitors $20.64 +0.99 (+5.04%) Closing price 04:00 PM EasternExtended Trading$20.64 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. PTCT, RYTM, CYTK, KRYS, ZLAB, ACAD, MRUS, SWTX, RNA, and RAREShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors PTC Therapeutics Rhythm Pharmaceuticals Cytokinetics Krystal Biotech Zai Lab ACADIA Pharmaceuticals Merus SpringWorks Therapeutics Avidity Biosciences Ultragenyx Pharmaceutical Enliven Therapeutics (NASDAQ:ELVN) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Do analysts recommend ELVN or PTCT? Enliven Therapeutics presently has a consensus target price of $41.20, suggesting a potential upside of 100.87%. PTC Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 32.41%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Enliven Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has preferable earnings and valuation, ELVN or PTCT? Enliven Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$89.02M-$1.92-10.68PTC Therapeutics$806.78M4.82-$363.30M$6.517.54 Which has more risk & volatility, ELVN or PTCT? Enliven Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Does the media favor ELVN or PTCT? In the previous week, PTC Therapeutics had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 9 mentions for PTC Therapeutics and 8 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.79 beat PTC Therapeutics' score of 0.02 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of ELVN or PTCT? 95.1% of Enliven Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is ELVN or PTCT more profitable? PTC Therapeutics has a net margin of 33.56% compared to Enliven Therapeutics' net margin of 0.00%. Enliven Therapeutics' return on equity of -31.84% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -31.84% -30.09% PTC Therapeutics 33.56%-78.56%32.11% SummaryEnliven Therapeutics and PTC Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$2.42B$5.50B$8.93BDividend YieldN/A1.79%5.38%4.12%P/E Ratio-10.678.9426.2519.86Price / SalesN/A665.31415.14113.78Price / CashN/A154.3736.4957.06Price / Book3.244.548.055.38Net Income-$89.02M$31.16M$3.16B$248.50M7 Day Performance-4.60%0.15%1.78%2.78%1 Month Performance7.16%8.74%4.74%5.84%1 Year Performance-5.48%2.17%35.81%20.06% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.4624 of 5 stars$20.64+5.0%$41.20+99.6%-13.4%$1.01BN/A-10.7550Analyst ForecastHigh Trading VolumePTCTPTC Therapeutics4.4113 of 5 stars$49.60-1.2%$65.00+31.0%+55.9%$3.98B$806.78M7.621,410Analyst RevisionRYTMRhythm Pharmaceuticals3.8956 of 5 stars$62.13+0.2%$76.62+23.3%+53.4%$3.94B$130.13M-22.11140CYTKCytokinetics4.2833 of 5 stars$32.64+0.6%$70.92+117.3%-38.5%$3.87B$19.22M-6.17250Positive NewsKRYSKrystal Biotech4.6181 of 5 stars$137.92+4.1%$211.13+53.1%-23.7%$3.83B$290.52M33.15210Analyst RevisionHigh Trading VolumeZLABZai Lab3.3837 of 5 stars$36.01+4.2%$47.37+31.5%+103.4%$3.81B$398.99M-14.461,869Positive NewsAnalyst ForecastInsider TradeAnalyst RevisionGap UpACADACADIA Pharmaceuticals4.6866 of 5 stars$22.48-1.0%$27.64+23.0%+33.2%$3.80B$957.80M16.41510MRUSMerus1.824 of 5 stars$52.74-0.7%$84.64+60.5%-3.3%$3.68B$36.13M-12.9337SWTXSpringWorks Therapeutics1.5382 of 5 stars$46.97+0.0%$52.57+11.9%+22.0%$3.54B$191.59M-13.77230RNAAvidity Biosciences2.1736 of 5 stars$29.15-0.5%$66.56+128.3%-31.1%$3.53B$10.90M-9.72190RAREUltragenyx Pharmaceutical3.9515 of 5 stars$36.83-0.8%$87.00+136.2%-11.8%$3.51B$560.23M-6.261,294 Related Companies and Tools Related Companies PTC Therapeutics Competitors Rhythm Pharmaceuticals Competitors Cytokinetics Competitors Krystal Biotech Competitors Zai Lab Competitors ACADIA Pharmaceuticals Competitors Merus Competitors SpringWorks Therapeutics Competitors Avidity Biosciences Competitors Ultragenyx Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
